Study for the add-on effect of vitamin K to Sorafenib treatment for hepatocellular carcinoma

Study for the add-on effect of vitamin K to Sorafenib treatment for hepatocellular carcinoma - Sorafenib + vitamin K therapy for HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007855

Enrollment

100

Registered

2012-04-28

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Srafenib + vitamin K combination therapy Sorafenib monotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis or compensated liver cirrhosis (Child-Pugh classification A), who do not have indication for either surgical resection nor radio frequency ablation or percutaneous ethanol infusion

Exclusion criteria

Exclusion criteria: Patients with uncontrollable infection

Design outcomes

Primary

Measure	Time frame
Effect for overall survival	—

Secondary

Measure	Time frame
Evaluation of safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026